OPI, Serena Williams launch Glam Slam! U.S. nail lacquers
LOS ANGELES — Tennis champion Serena Williams joined OPI co-founder Suzi Weiss-Fischmann at a New York City event on Aug. 25 to officially launch the final series of nail lacquers in her Glam Slam! by OPI promotion, which kicked off earlier this year.
The colors included in the Glam Slam! U.S. limited-edition duo-pack are a shimmering red named Love is a Racket and a glittering bronze titled Pros & Bronze.
"It has been so wonderful to work with Serena. She has a fierce passion for nails and knows how to make a fashion statement both on and off the court," stated Weiss-Fischmann. "Serena helped us to create tones that exemplify her personality and style. Packed with shimmer and highly pigmented, all 11 shades, including three Shatter hues, have been hugely successful."
The Glam Slam! promotion kicked off in January, with the global premiere of OPI’s Black Shatter coat. New shades have been launched throughout the year in conjunction with Grand Slam tournament dates, beginning with Glam Slam! Australia and followed by France, England and now the United States. During a guest appearance on “Oprah” in late 2010, Williams revealed her love for nails and unofficially announced her partnership with OPI, with each audience member receiving an OPI manicure to showcase on-screen.
Glam Slam! lacquers currently are available at professional salons nationwide.
Pfizer, BMS drug more effective than warfarin in AF patients
NEW YORK — A drug made by Pfizer and Bristol-Myers Squibb undergoing late-stage clinical trials was more effective than the generic drug warfarin in patients with atrial fibrillation, according to study results released Sunday.
The phase-3 "ARISTOTLE" trial of Eliquis (apixaban) showed that the drug reduced the risk of stroke and systemic embolism by 21%, major bleeding by 31% and death by 11% in AF patients. The study, published in the New England Journal of Medicine, was conducted at 1,034 centers in 39 countries and enrolled 18,201 patients.
"The risk for stroke in patients with atrial fibrillation is a major public health concern in an aging population," Duke University Medical Center professor of medicine and lead study investigator Christopher Granger said. "We are therefore encouraged by the outcome of the ARISTOTLE trial, which showed that apixaban, as compared with warfarin, significantly reduced the risk of stroke or systemic embolism, major bleeding and mortality."
NACDS’ Anderson urges embracement of pharmacy’s ability to cut costs, improve lives
BOSTON — National Association of Chain Drug Stores president and CEO Steve Anderson emphasized the value of pharmacy for payers and patients, and hailed the industry as one whose “future vision is nothing short of transformative,” during his remarks at Monday morning’s business session at the NACDS Pharmacy and Technology Conference.
Placing community pharmacy in the context of crises facing the country and the world, Anderson emphasized its collaboration with payers to help reduce healthcare costs, while cautioning that the evaluation of healthcare economics must be conducted with a comprehensive view of patient-focused pharmacy services.
"This is an industry whose future vision is nothing short of transformative — with the ability to fashion a more cost-effective, more efficient and more successful healthcare delivery system," Anderson said. "But still, this is also an industry for whose viability we need to fight at every turn."
Among programs he highlighted was ChecKmeds NC, a program in North Carolina in which Medicare patients have access to face-to-face medication therapy management services that have delivered a return on investment of $13.55 for each $1 invested.
"While we understand the situation and recognize the need for immediate savings, everyone needs to understand something about pharmacy: We are not going to back down on the central argument of our industry," Anderson said. "By keeping patients healthier and preventing the need for more costly forms of care, pharmacy lowers costs across the board. And to arbitrarily cut prescription drug costs is to see other costs — even greater costs — pop up in other places."
Anderson also touted NACDS’ progress in transforming into a "more powerful and focused association" acting on members’ behalf. "NACDS is the nexus of where business, politics and public policy come together for the betterment of industry, but, more importantly, for the betterment of the American people. NACDS has filled a vacuum and added value through better collaboration with our allies, more spirited communications, grassroots advocacy, impacting elections through the NACDS Political Action Committee and creating a focus on winning in federal and state government affairs by shaping legislation and regulations and battling in the courts when needed,” Anderson said.